Therefore, USAMMDA has made the development of a commercially available source of freeze-dried plasma a top priority.
In April 2014, Vascular Solutions entered into a Cooperative Research and Development Program with USAMMDA. Under the CRADA, USAMMDA provides funding for the regulatory and clinical work, and Vascular Solutions owns all intellectual property and commercial rights to the product.
USAMMDA is responsible for sponsoring, managing, and funding all preclinical and clinical studies required to support a Biologic License Application for commercialization.
Due to the difficulty of using current forms of plasma in remote locations such as in theater medical facilities and battlefield situations, USAMMDA has sought the development of a stable, durably-packaged freeze-dried plasma product that can be easily stored, transported, and administered in remote conditions.